Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940432 | 0.90 | MKNK1 (0.82) | MKNK1FYN | |
| SCHEMBL16429515 | 0.86 | MKNK1 (0.82) | MKNK1FYN | |
| SCHEMBL13859380 | 0.86 | MKNK1 (0.77) | MKNK1FYN | |
| SCHEMBL2947494 | 0.85 | MKNK1 (0.75) | MKNK1FYN | |
| SCHEMBL13859442 | 0.84 | MKNK1 (0.74) | MKNK1FYN | |
| SCHEMBL13859103 | 0.83 | MKNK1 (0.73) | MKNK1FYN | |
| SCHEMBL15921162 | 0.83 | MKNK1 (1.00) | MKNK1 | |
| SCHEMBL2948001 | 0.82 | MKNK1 (1.00) | MKNK1FYN | |
| SCHEMBL16117420 | 0.81 | MKNK1 (0.74) | MKNK1FYN | |
| SCHEMBL2949374 | 0.81 | MKNK1 (0.77) | MKNK1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| EP-2920176-B1 | AMINOIMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| EP-2714692-B1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| EP-2723748-B1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-9284319-B2 | Heterocyclyl aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-20150291599-A1 | AMINOIMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| WO-2014076162-A1 | AMINOIMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-22 | — | — | WO | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291599-A1 | AMINOIMIDAZOPYRIDAZINES | CCND2, CCND1, CCNI | MKNK1 3235/4885FYN 2727/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | MKNK1 144/4885FYN 421/4885 |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | CCND2, CCND1, VEGFA | MKNK1 3763/4885FYN 2261/4885 |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | MKNK1, MKNK2, MAP4K5 | MKNK1 1/4885FYN 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.